Skip to content
Human trials of nasal Alzheimer’s vaccine to begin in Boston

The first human trial of a nasal vaccine to prevent Alzheimer’s disease is expected to begin at a Boston hospital. The vaccine is entering phase 1 of clinical trials and is the result of 20 years of research.

Alzheimer’s disease is the most common form of dementia. Dementia is a general term for the cognitive decline seen in older people. Statistics indicate that a person is diagnosed with dementia every 3 seconds worldwide with over 10 million new cases each year.

Alzheimer’s disease is a progressive disease that destroys memory and other important mental functions. The main symptoms are memory loss and confusion.

The vaccine is a 2-dose nasal spray that will be given 1 week apart. He will use a chemical called Protollin to boost the immune system and activate white blood cells.

Watch the video to learn more.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.